A large number of patients with osteoporosis are not receiving appropriate treatment, due in part to concerns regarding drug safety. Great progress has been made to address this crisis in therapy in 2017, including highlighting the patients' views, developing new therapies and treatment strategies and addressing these safety concerns.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
214,86 € per year
only 17,91 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kalluru, R. et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open 7, e013703 (2017).
Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017).
Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteo-porosis. N. Engl. J. Med. 377, 1417–1427 (2017).
Kendler, D. L. et al. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicenter, double-blind, double-dummy, randomized controlled trial. Lancet 10.1016/S0140-6736(17)32137-2 (2017).
Khosla, S. et al. A crisis in the treatment of osteoporosis. J. Bone Miner. Res. 31, 1485–1487 (2016).
Alami, S. et al. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients' and practitioners' views. PLoS ONE 11, e0158365 (2016).
Cummings, S. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
Miller, P. D. et al. Effects of abaloparatide versus placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316, 722–733 (2016).
Cosman, F. et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatement with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin. Proc. 92, 200–210 (2017).
Cosman, F. et al. Romosozumab treatment in post menopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Roux, C., Briot, K. Addressing the crisis in the treatment of osteoporosis. Nat Rev Rheumatol 14, 67–68 (2018). https://doi.org/10.1038/nrrheum.2017.218
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.218
This article is cited by
-
Gastrointestinal health and serum proteins are associated with BMD in postmenopausal women: a cross-sectional study
Nutrition & Metabolism (2024)
-
Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases
Cell Death Discovery (2024)
-
The clinician’s guide to prevention and treatment of osteoporosis
Osteoporosis International (2022)
-
Serum exosomes from young rats improve the reduced osteogenic differentiation of BMSCs in aged rats with osteoporosis after fatigue loading in vivo
Stem Cell Research & Therapy (2021)
